BNP/CALL/GSK PLC/1600/1/20.12.24 Share Price

Warrant

DE000PC3G6A6

Market Closed - Boerse Frankfurt Warrants 08:51:27 03/07/2024 pm IST
0.75 EUR 0.00% Intraday chart for BNP/CALL/GSK PLC/1600/1/20.12.24
Current month-13.79%
1 month-47.92%
Date Price Change
03/24/03 0.75 0.00%
02/24/02 0.75 -15.73%
01/24/01 0.89 +2.30%
28/24/28 0.87 +2.35%
27/24/27 0.85 -33.59%

Real-time Boerse Frankfurt Warrants

Last update July 03, 2024 at 08:51 pm IST

More quotes

Static data

Product typeWarrants
Buy / SellCALL
Underlying GSK PLC
IssuerLogo Issuer BNP Paribas BNP Paribas
WKN PC3G6A
ISINDE000PC3G6A6
Date issued 18/01/2024
Strike 1,600 p
Maturity 20/12/2024 (170 Days)
Parity 1 : 1
Emission price 1.36
Emission volume N/A
Settlement règlement en espèces
Currency EUR

Technical Indicators

Highest since issue 3.16
Lowest since issue 0.66
Delta0.43x
Omega 10.03
Premium10.67x
Gearing23.53x
Moneyness 0.9397
Difference Strike 96.5 p
Difference Strike %+6.03%
Spread 0.01
Spread %1.32%
Theoretical value 0.7550
Implied Volatility 21.64 %
Total Loss Probability 63.06 %
Intrinsic value 0.000000
Present value 0.7550
Break even 1,663.87 €
Theta-0.03x
Vega0.05x
Rho0.03x

Company Profile

GSK plc is a global biopharma company. The Company’s segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. Its product areas include vaccines, specialty medicines, and general medicine. It is also focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions. Its vaccine portfolio includes over 20 vaccines that help to protect people from a range of diseases and infections, including meningitis, shingles and flu, among others. Its specialty medicines are also engaged in developing medicines for respiratory disease and HIV. Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease, antibiotics, and medicines for skin diseases. It is advancing oligonucleotide therapeutics in chronic hepatitis B and steatotic liver disease as well as other therapeutic areas beyond liver disease.
Sector
-
More about the company

Ratings for GSK plc

Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings

Consensus: GSK plc

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
22
Last Close Price
15.04 GBP
Average target price
20.28 GBP
Spread / Average Target
+34.91%
Consensus